Krankenanstalt Rudolfstiftung, Second Medical Department, Juchgasse 25, Wien A-1030, Austria.
Pharmaceuticals (Basel). 2012 Feb 3;5(2):155-68. doi: 10.3390/ph5020155.
Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
达比加群酯是一种口服凝血酶抑制剂，已在多个国家获得批准，可作为维生素 K 拮抗剂的替代品，用于预防心房颤动患者的中风或栓塞。达比加群酯已被引入临床实践，但关于这种药物仍有许多问题尚不清楚，如实验室监测、在老年患者中的应用、药物和食物相互作用以及在肾功能不全患者中的应用。此外，达比加群酯没有解毒剂。因此，本综述的目的是概述达比加群酯的相关关注点和未解决的问题。
